Back

Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)

30 August 2026 (14:45 - 15:00)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition Cardiovascular Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Carolyn S P Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)

4 More presentations in this session

Presentation thumbnail
Effects of finerenone in patients with hypertensive nephropathy
Professor H. Heerspink (Groningen, NL)
Slides Video
Presentation thumbnail
Extended Follow-Up of the KARDINAL Trial Assessing the Effect of Tonlamarsen in Uncontrolled Hypertension
Associate Professor L. Laffin (Cleveland, US)
Slides Video
Presentation thumbnail
Aldosterone suppression is more effective than blood pressure reduction in reversing cardiac remodelling due to primary aldosteronism: the MATCH and PATHWAY-1 prospective CMR sub-studies
Doctor J. Wilson (London, GB)
Slides Video
Presentation thumbnail
Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial
Professor B. Williams (London, GB)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 14:45 CET
You may be interested in
thumbnail
Congress Presentation
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes
1 September 2024
thumbnail
Congress Session
Young Investigator Award Session in Preventive Cardiology
31 August 2024
thumbnail
Congress Presentation
Finerenone use in CKD and T2D: from clinical trials to the clinic.
28 August 2022
thumbnail
Congress Presentation
Finerenone versus spironolactone in HFpEF patients with type 2 diabetes and CKD: a real-world comparative analysis
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources